UMDNJ

Cepheid's Xpert MTB/RIF test received a vote of confidence for its ability to diagnose TB and rifampicin resistance in remote and resource-poor regions of the world, according to the results of a New England Journal of Medicine study.

Princeton University, Point-2-Point Genomics, PHRI at UMDNJ/NJMS, and NuGen Technologies awarded US patents.

Under the deal, Biosearch has the exclusive rights to manufacture, catalogue, and sell validated RNA FISH probes, assays, and kits in the research, applied markets, and in vitro diagnostic fields.

The UK-based company will offer the toolkit through a single license that combines IP it licensed from Brandeis University and PHRI Properties, the tech-transfer arm of the University of Medicine and Dentistry of New Jersey.

Cepheid and the University of Medicine and Dentistry of New Jersey will work on developing a 10-color detection technology for the firm's GeneXpert System.

Pages

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.